We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+2.31%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$3.71B
AUM Growth
+$121M
Cap. Flow
+$218M
Cap. Flow %
5.87%
Top 10 Hldgs %
63.73%
Holding
72
New
5
Increased
8
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$120M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$47.8M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$38.2M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$31.6M
5
ROIV icon
Roivant Sciences
ROIV
+$31M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$67.5M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$10.1M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$9.73M
4
RLAY icon
Relay Therapeutics
RLAY
+$8.12M
5
ITOS
iTeos Therapeutics
ITOS
+$7.05M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ROIV icon
26
Roivant Sciences
ROIV
$24.5B
$32M 0.86%
+2,742,409
New +$31M
CGEM icon
27
Cullinan Oncology
CGEM
$1.02B
$28.9M 0.78%
3,196,701
– –
ETNB
28
DELISTED
89bio
ETNB
$28.5M 0.77%
1,846,154
– –
THRD
29
DELISTED
Third Harmonic Bio
THRD
$27.9M 0.75%
4,365,933
– –
EPIX
30
DELISTED
ESSA Pharma
EPIX
$27M 0.73%
8,748,629
– –
OVID icon
31
Ovid Therapeutics
OVID
$420M
$26.3M 0.71%
6,851,051
– –
ANTX icon
32
AN2 Therapeutics
ANTX
$195M
$25.1M 0.68%
1,563,963
– –
LXRX icon
33
Lexicon Pharmaceuticals
LXRX
$1.03B
$21.8M 0.59%
19,995,332
– –
ACIU icon
34
AC Immune
ACIU
$226M
$21.2M 0.57%
7,428,379
– –
RLAY icon
35
Relay Therapeutics
RLAY
$4.09B
$19.9M 0.54%
2,365,805
-754,716
-24% -$8.12M
ALLK
36
DELISTED
Allakos
ALLK
$19.4M 0.52%
8,552,417
-100,000
-1% -$371K
SLN
37
Silence Therapeutics
SLN
$527M
$14.8M 0.4%
1,508,416
– –
CBIO
38
Crescent Biopharma
CBIO
$530M
$14.3M 0.39%
95,443
– –
NAMS icon
39
NewAmsterdam Pharma
NAMS
$3.26B
$14.1M 0.38%
1,521,948
– –
ITOS
40
DELISTED
iTeos Therapeutics
ITOS
$13.8M 0.37%
1,259,476
-551,359
-30% -$7.05M
IMA
41
ImageneBio Inc
IMA
$62.9M
$13.7M 0.37%
264,097
– –
VSTM icon
42
Verastem
VSTM
$490M
$13.7M 0.37%
1,685,219
– –
CALT
43
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$13.7M 0.37%
750,000
– –
STRO icon
44
Sutro Biopharma
STRO
$410M
$11.6M 0.31%
334,795
– –
IMVT icon
45
Immunovant
IMVT
$7.9B
$11.5M 0.31%
+300,000
New +$6.78M
VIGL
46
DELISTED
Vigil Neuroscience
VIGL
$9.78M 0.26%
1,813,633
– –
VERV
47
DELISTED
Verve Therapeutics
VERV
$8.62M 0.23%
650,000
– –
CTMX icon
48
CytomX Therapeutics
CTMX
$675M
$8.51M 0.23%
6,595,801
– –
TCRX icon
49
TScan Therapeutics
TCRX
$49.1M
$7.65M 0.21%
2,989,474
– –
JSPR icon
50
Jasper Therapeutics
JSPR
$19.7M
$6.93M 0.19%
990,000
– –
1
2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2023 Portfolio in Review

As of Q3 2023, BVF Inc held 72 positions worth $3.71B, up 3.4% from $3.59B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

BVF Inc deployed $218M of net new capital in Q3 2023, opening 5 new positions and adding to 8 existing holdings. Its largest new stake was Mirum Pharmaceuticals: 4,370,024 shares worth $138M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Revolution Medicines, an estimated $67.5M trimmed.

  • BVF Inc's largest Q3 2023 buy was Mirum Pharmaceuticals: 4,370,024 shares worth $138M.
  • BVF Inc added most to Ionis Pharmaceuticals in Q3 2023, an estimated $47.8M increase.
  • BVF Inc's biggest Q3 2023 reduction was Revolution Medicines, cutting an estimated $67.5M.
  • BVF Inc fully exited Aravive, Inc. Common Stock in Q3 2023, selling an estimated $6.03M.
  • BVF Inc's ten largest holdings make up 64% of its $3.71B portfolio in Q3 2023.
  • BVF Inc opened 5 new positions and closed 3 in Q3 2023.
  • BVF Inc's portfolio value rose 3.4% quarter-over-quarter to $3.71B.

Based on BVF Inc's 13F filing for Q3 2023, filed 14 Nov 2023.